I believe there would be a general agreement on the fact that companies in today’s world need to innovate to survive. However, the conundrum is how much of the company’s revenue (small/medium enterprises) or initial funds (as for start-ups) be focused on the research activity?
Let us take examples of two types of business models (we would only consider biotech/life science industry). First is the ‘service’ model where the companies provide technological services for fee. These might range from providing protein purification services to next generation sequencing. The companies rely on their expertise and promote their cause by trying to give the best services. Since many of the companies utilize an already known technology they focus on giving their clients the best technological support and in due course would expect good ‘word of mouth’ publicity for the company to promote its services. The better companies which survive for the longest duration however are also focused on improving the ‘in –use’ technologies to sharpen their service portfolio. This is crucial as the subtle improvements can bring in new clients and can also cater better to the existing client base. One general question can be since these companies utilize instruments or reagents from established players (Illumina, Agilent etc.) why should the service provider invest money to innovate? Surely the instrument manufacturers are doing their bit and the service providers can acquire the technology from them! So why not completely focus on marketing and spend little on ‘in-house’ research? Well, research does not always mean big ticket breakthroughs! Even subtle changes for example, in the protocol of a particular assay can bring in great benefits both in terms of economic advantage as well as technological advancement. Second is that newer methods can provide a valuable feedback to the instrument manufacturers and therefore the possibility of partnership increases. This gives a huge fillip to the ‘brand value’ of the service provider. Hence one cannot completely shut innovation even in service based business models.
Let us now look at the ‘product’ based business model (again in the realms of life science industry). I guess there is no denying the fact that for product based life science organizations ranging from companies delivering ‘bioinformatics suite’ to companies selling enzymes, innovation has to take the primary seat. Newer and better products are the keys to survival!
But having known these facts how many SMEs (Small medium enterprises) really focus on innovation? Many companies think that money spent on R&D is not worth it especially in the life science sector as there is a long incubation period and higher failure rates. But then investing in research is like buying insurance. Not only the companies need to invest but invest in the right idea and people to continue surviving in this fast paced era!
About the author: Dr Debojyoti Dhar, PhD (Indian Institute of Science, IISc) has over 10 years experience in academic and industry ‘research and development’ (R&D) activities along with strong multi domain knowledge in pharmaceutical and biotechnology industries. He has worked extensively on translational control of gene regulation during his PhD (Indian Institute of Science, IISc) and post doctoral research (UMass Medical School, USA).
Dr Dhar has also worked on diabetes and metabolic syndrome at Connexios Life sciences, a drug discovery company based in India. He has held leadership positions in various companies with roles in R&D, Business Development, Corporate Communications and Consultancy and has thorough knowledge on new cutting edge technologies in the bio-science space. An avid reader with keen interest in quantum physics and holistic medicine, Dr Dhar writes a blog on disease, research and its impact on society and life science industry in general (www.debiisc.blogspot.in). Dr Dhar has to his credit various publications in top-tiered peer reviewed journals and has attended and presented lectures at many conferences and Institutes.
At present, Dr Dhar is Director at Leucine Rich Bio Pvt Ltd., a bioinformatics driven organization. He takes care of the business development, corporate communications activities apart from spearheading innovation and general management of the organization.
https://in.linkedin.com/in/dr-debojyoti-dhar-8a1b5717
This work by ClubSciWri is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
